Form 4: Verve Therapeutics CEO Awarded Stock Options and Restricted Stock Units

Verve Therapeutics CEO, Sekar Kathiresan, received stock options and restricted stock units on January 8, 2025, as part of his compensation.

Summary

• Sekar Kathiresan, CEO of Verve Therapeutics, was granted stock options for 488,000 shares at an exercise price of $6.01 on January 8, 2025.
• These options vest over time, with 25% vesting on January 8, 2026, and the remainder vesting monthly until January 8, 2029.
• Kathiresan also received 120,000 restricted stock units (RSUs) that vest in three equal annual installments starting April 1, 2026.
• An additional 150,000 stock options were granted, which vest immediately if the stock price reaches $20.00 for 15 consecutive trading days before January 8, 2027.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which are generally viewed positively as they align management's interests with shareholders. The performance-based vesting is a positive signal.

Positives

• The grant of stock options and restricted stock units aligns the CEO's interests with those of the shareholders.
• The vesting schedule of the options and RSUs encourages long-term performance and retention of the CEO.
• The performance-based vesting of the additional 150,000 stock options incentivizes the CEO to drive the stock price higher.

Risks

• The stock price may not reach the $20.00 target required for the immediate vesting of the 150,000 stock options.
• The vesting of the options and RSUs could lead to dilution of existing shareholders if the options are exercised.

Future Outlook

The document outlines the vesting schedule for the stock options and restricted stock units, which are tied to the CEO's continued employment and, in one case, the company's stock performance.

Industry Context

The granting of stock options and restricted stock units is a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for CEOs in the biotech industry, often with vesting schedules tied to performance and tenure.
• The vesting schedule of the options and RSUs is typical, with a mix of time-based and performance-based vesting.
• The $20.00 stock price target for the additional options is a common way to align executive compensation with shareholder value creation.

Stakeholder Impact

• Shareholders may view the grants positively as they align the CEO's interests with the company's performance.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, executive compensation, vesting, Sekar Kathiresan, Verve Therapeutics, equity awards